Abstract
Scalable 3D Screen Printing Technology in Pharmaceutical Manufacturing - High Degree of Freedom in Terms of Drug Choice
Highlights
Additive manufacturing has the potential to revolutionize the pharmaceutical industry, enabling the production of customized drugs for the mass market
We reported in Moldenhauer et al [2] the first proofof-concept study on 3D screen printing, termed SPID® (Screen Printing Innovational Drug Technology), in the fabrication of a drug delivery system (DDS). 3D screen printing uses a screen mesh to transfer a semi-solid, active pharmaceutical ingredient (API) containing paste onto a substrate, except in areas made impermeable by a blocking stencil
Key advantages of screen printing versus other 3D printing technologies are the high freedom in choice of materials and the number of tablets able to be produced at one time. 3D screen printing enables the build-up of thousands of units per screen
Summary
Additive manufacturing has the potential to revolutionize the pharmaceutical industry, enabling the production of customized drugs for the mass market. Each uses its own method to deposit and cure the material These limitations are highlighted by the fact that there is only a single 3D printed medicine, Spritam® (an antiepileptic) that is currently FDA approved and marketed [1]. Key advantages of screen printing versus other 3D printing technologies are the high freedom in choice of materials and the number of tablets able to be produced at one time. 3D screen printing enables the build-up of thousands of units per screen This is in stark contrast to other 3DP technologies that can only produce one tablet per printing head at the same time [5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
